1CHRISTOPHER J, GANNON MD, STEVEN A, et al.The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors[J]. Semin Radiat Oncol,2005,15 (4):265-272.
2LIU MT, LI SH, CHU LH, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization [J]. Jap J Clin Oncol, 2004,34(9):532-539.
4LIANG SX, JIANG GL, LU HL, et al. Hypofractionated three-dimensional conforrnal radiation therapy for primary liver carcinoma[J]. Cancer, 2005,103 (10):2181-2188.
5ZENG ZC, TANG ZY, ZHOU J, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus [J]. Int J Radiat Oncol Biol Phys, 2005,61(2):432-433.
6PARK W, LIM H, PAIK SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2005, 61(4): 1143-1150.
7BEN-JOSEF E, NORMOLLE D, ENSMINGER WD, et al. Phase Ⅱ trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies[J]. J Clin Oncol. 2005,23(34) : 8739-8747.
8FAJARDO LF. The pathology of ionizing radiation as defined by morphologic patterns[J]. Acta Oncol. 2005,44(1):13-22.
9DAWSON LA, TEN HAKEN PK. Partial volume tolerance of the liver to radiation[J]. Semin Radiat Oncol,2005,15(4):279-283.
10CHENG CH, LIU HS, WU JK, et al. Inclusion of biological facrtors in parallel-architecrure normal-tissue complication probability model for radiation-induced liver disease[J]. Int J Radiat Oncol Biol Phys, 2005, 62(4):1150-1156.
6Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? [J] Matrix Biol, 2002,21: 473-482.
7Miranda-Diaz A, Rincon AR, Salgado S, et al. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis[J]. Mol Ther, 2004,9:30-37.
8Solis-Herruzo JA, de la Torre P, Munoz-Yague MT. Hepatic stellate cells (HSC): architects of hepatic fibrosis[J]. Rev Esp Enferm Dig, 2003, 95: 438-439.
9Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation[J]. Med Gen Med, 2002,4: 27-30.
10Friedman SL. Liver fibrosis-from bench to bedside[J]. J Hepatol,2003,8(supple1): S38-S53.
7Bankova V,Krasteva GB,Popov S,et al.Seasonal variations of the chemical composition of Brazilian propolis[J].Apidologie,1998,29:361-367.
8Banskota AH,Tezuka Y,Adnyana IK,et al.Cytotoxic,hepatoprotective and free radical scavenging effects of propolis from Brazil,Peru,the Netherlands and China[J].Ethnopharmacol,2000,72:239-246.
9Sforcin JM.Propolis and the immune system:a review[J].Ethnopharmacol,2007,113:1-14.
10Padmavathi R,Senthilnathan P,Sakthisekaran D,et al.Therapeutic effect of propolis and paclitaxel on hepatic phase I and II enzymes and marker enzymes in dimethylbenz(a) anthracene-induced breast cancer in female rats[J].Comp Biochem Physiol C Toxicol Pharmacol,2006,143:349-354.
